癌研連線CancerLink
進行中（不再收案） NCT03164616

Durvalumab + Tremelimumab 聯合化療或 Durvalumab 聯合化療或單獨化療用於肺癌患者的研究（POSEIDON）

非小細胞肺癌淋巴瘤肉瘤Phase IIIIII 期IV 期EGFRALKPD-L1

這是一項隨機、開放標籤、多中心、全球性第三期研究，旨在確定 durvalumab + tremelimumab 聯合治療 + 標準治療（SoC）化療或 durvalumab 單藥治療 + SoC 化療與單獨 SoC 化療相比，作為轉移性非小細胞肺癌（NSCLC）患者第一線治療的療效和安全性，這些患者的腫瘤缺乏激活型表皮生長因子受體（EGFR）突變和間變性淋巴

適應症：Non Small Cell Lung Cancer NSCLC

收案條件

納入條件

  • For inclusion in the study, patients should fulfill the following criteria:
  • Aged at least 18 years.
  • Histologically or cytologically documented Stage IV NSCLC.
  • Confirmed tumor PD-L1 status prior to randomization.
  • Patients must have tumors that lack activating EGFR mutations and ALK fusions.
  • No prior chemotherapy or any other systemic therapy for metastatic NSCLC.
  • World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • No prior exposure to immunemediated therapy, excluding therapeutic anticancer vaccines.

排除條件

  • Mixed small-cell lung cancer and NSCLC histology, sarcomatoid variant.
  • Active or prior documented autoimmune or inflammatory disorders.
  • Brain metastases or spinal cord compression unless the patient's condition is stable and off steroids.
  • Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus.

收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。